Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

93.19
+3.263.63%
Post-market: 93.190.00000.00%19:30 EDT
Volume:1.24M
Turnover:114.72M
Market Cap:8.22B
PE:-46.36
High:95.27
Open:91.16
Low:90.48
Close:89.93
52wk High:110.18
52wk Low:15.86
Shares:88.17M
Float Shares:80.98M
Volume Ratio:0.96
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:8.61
PE(LYR):-47.17

Loading ...

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and Tyra Bioscience (TYRA)

TIPRANKS
·
Jun 16

Spyre says bowel disease drug cuts inflammation in mid-stage trial

Reuters
·
Jun 15

Spyre Therapeutics announces SKYLINE trial achieves primary endpoint

TIPRANKS
·
Jun 15

Spyre says SPY002 hits primary endpoint in Phase 2 SKYLINE ulcerative colitis trial Part A induction data

Reuters
·
Jun 15

Spyre Therapeutics - Spy002 Meets Primary Endpoint With 10.7-Point Rhi Reduction at Week 12

THOMSON REUTERS
·
Jun 15

Spyre Announces Potential Best-in-Class Spy002 (Anti-Tl1a) Part a Induction Results From Skyline Trial in Moderate-to-Severe Ulcerative Colitis Patients

THOMSON REUTERS
·
Jun 15

Spyre Therapeutics - Spy002 Well Tolerated With Safety Profile Consistent With Tl1a Class

THOMSON REUTERS
·
Jun 15

Spyre Therapeutics - Spy002 Achieves 33% Clinical Remission and 42% Endoscopic Improvement at Week 12

THOMSON REUTERS
·
Jun 15

Spyre Therapeutics - Twenty Subjects Had Treatment-Emergent Adverse Events; Two Serious, None Drug-Related

THOMSON REUTERS
·
Jun 15

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

GlobeNewswire
·
Jun 15

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF)

TIPRANKS
·
Jun 15

S&P 500 Futures Climb In Premarket Trading; Navan, AXT Lead

Dow Jones
·
Jun 11

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Jun 06

Spyre Therapeutics : Deutsche Bank Raises Target Price to $115 From $102

THOMSON REUTERS
·
Jun 04

Spyre Therapeutics CMO Sheldon Sloan disposes of USD 624,975 in common shares

Reuters
·
Jun 04

Spyre Therapeutics CEO Cameron Turtle disposes of USD 1.04 million in common shares

Reuters
·
Jun 04

Spyre Therapeutics CFO Scott L Burrows disposes of common shares worth $534,123.87

Reuters
·
Jun 04

Assessing Spyre Therapeutics (SYRE) Valuation After Expanded SPY003 License With Paragon

Simply Wall St.
·
Jun 04

Spyre Therapeutics Completes Enrollment in Phase 2 SKYWAY Trial of SPY072 in Rheumatic Diseases

MT Newswires Live
·
Jun 03

Spyre Therapeutics - Across Skyway and Skyline Trials, Planned ‘6 in ’26’ Phase 2 Readouts Enabled and on Track

THOMSON REUTERS
·
Jun 03